Titre : Franchises et coassurance

Franchises et coassurance : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interleukin-1
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Franchises et coassurance : Questions médicales les plus fréquentes", "headline": "Franchises et coassurance : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Franchises et coassurance : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Franchises et coassurance" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Participation aux coûts", "url": "https://questionsmedicales.fr/mesh/D017047", "about": { "@type": "MedicalCondition", "name": "Participation aux coûts", "code": { "@type": "MedicalCode", "code": "D017047", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.219.521.576.090" } } }, "about": { "@type": "MedicalCondition", "name": "Franchises et coassurance", "alternateName": "Deductibles and Coinsurance", "code": { "@type": "MedicalCode", "code": "D003669", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "J Frank Wharam", "url": "https://questionsmedicales.fr/author/J%20Frank%20Wharam", "affiliation": { "@type": "Organization", "name": "Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA." } }, { "@type": "Person", "name": "Alisa B Busch", "url": "https://questionsmedicales.fr/author/Alisa%20B%20Busch", "affiliation": { "@type": "Organization", "name": "Department of Health Care Policy, Harvard Medical School." } }, { "@type": "Person", "name": "Fang Zhang", "url": "https://questionsmedicales.fr/author/Fang%20Zhang", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Dennis Ross-Degnan", "url": "https://questionsmedicales.fr/author/Dennis%20Ross-Degnan", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Mark K Meiselbach", "url": "https://questionsmedicales.fr/author/Mark%20K%20Meiselbach", "affiliation": { "@type": "Organization", "name": "Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interleukin-38 in atherosclerosis.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36150521", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cca.2022.09.017" } }, { "@type": "ScholarlyArticle", "name": "Interleukin 1α and interleukin 18 in patients with vitiligo - Results of a case-control study.", "datePublished": "2023-02-03", "url": "https://questionsmedicales.fr/article/36739764", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2023.114364" } }, { "@type": "ScholarlyArticle", "name": "The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35621220", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/art.42139" } }, { "@type": "ScholarlyArticle", "name": "The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35623638", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/annrheumdis-2021-221801" } }, { "@type": "ScholarlyArticle", "name": "Estimation of Interleukin 32 and Interleukin 37 Serum Levels in Iraqi Patients with Rheumatoid Arthritis.", "datePublished": "2023-04-30", "url": "https://questionsmedicales.fr/article/37396740", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.22092/ARI.2022.359861.2489" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Économie", "item": "https://questionsmedicales.fr/mesh/D004467" }, { "@type": "ListItem", "position": 4, "name": "Financement organisé", "item": "https://questionsmedicales.fr/mesh/D005381" }, { "@type": "ListItem", "position": 5, "name": "Assurance", "item": "https://questionsmedicales.fr/mesh/D007341" }, { "@type": "ListItem", "position": 6, "name": "Participation aux coûts", "item": "https://questionsmedicales.fr/mesh/D017047" }, { "@type": "ListItem", "position": 7, "name": "Franchises et coassurance", "item": "https://questionsmedicales.fr/mesh/D003669" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Franchises et coassurance - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Franchises et coassurance", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Franchises et coassurance", "description": "Qu'est-ce qu'une franchise en assurance santé ?\nComment fonctionne la coassurance ?\nQuelle est la différence entre franchise et coassurance ?\nComment sont calculées les franchises ?\nLes franchises sont-elles remboursables ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Franchises et coassurance", "description": "Quels sont les impacts d'une franchise élevée ?\nComment la coassurance affecte-t-elle les patients ?\nLes patients ressentent-ils du stress à cause des franchises ?\nLes franchises influencent-elles la santé des patients ?\nY a-t-il des symptômes financiers liés à la coassurance ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Franchises et coassurance", "description": "Comment éviter des frais élevés de franchise ?\nLes bilans de santé sont-ils couverts sans franchise ?\nComment éduquer les patients sur les franchises ?\nLes programmes de prévention réduisent-ils les coûts ?\nComment les patients peuvent-ils planifier leurs soins ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Franchises et coassurance", "description": "Comment choisir un plan avec franchise ?\nLes traitements préventifs sont-ils couverts ?\nComment réduire les coûts de coassurance ?\nLes médicaments sont-ils soumis à la franchise ?\nLes soins d'urgence sont-ils affectés par la coassurance ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Franchises et coassurance", "description": "Quelles complications peuvent survenir avec des franchises élevées ?\nLa coassurance peut-elle entraîner des complications financières ?\nLes patients évitent-ils des soins à cause des coûts ?\nComment les complications de santé affectent-elles les coûts ?\nLes complications dues à la coassurance sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Franchises et coassurance", "description": "Quels facteurs augmentent les coûts de franchise ?\nComment le choix de l'assurance affecte-t-il les coûts ?\nLes maladies chroniques augmentent-elles les frais ?\nLes jeunes adultes ont-ils des franchises plus basses ?\nLes habitudes de santé influencent-elles les coûts ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Interleukin-1&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Qu'est-ce qu'une franchise en assurance santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "C'est le montant que le patient doit payer avant que l'assurance ne couvre les frais." } }, { "@type": "Question", "name": "Comment fonctionne la coassurance ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "C'est le pourcentage des frais médicaux que le patient doit payer après la franchise." } }, { "@type": "Question", "name": "Quelle est la différence entre franchise et coassurance ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La franchise est un montant fixe, tandis que la coassurance est un pourcentage des frais." } }, { "@type": "Question", "name": "Comment sont calculées les franchises ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont généralement fixées par le contrat d'assurance et varient selon les plans." } }, { "@type": "Question", "name": "Les franchises sont-elles remboursables ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, les montants de franchise ne sont pas remboursés par l'assurance." } }, { "@type": "Question", "name": "Quels sont les impacts d'une franchise élevée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une franchise élevée peut dissuader les patients de consulter des soins médicaux." } }, { "@type": "Question", "name": "Comment la coassurance affecte-t-elle les patients ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des coûts supplémentaires pour les patients lors de soins médicaux." } }, { "@type": "Question", "name": "Les patients ressentent-ils du stress à cause des franchises ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les coûts imprévus peuvent causer de l'anxiété financière chez les patients." } }, { "@type": "Question", "name": "Les franchises influencent-elles la santé des patients ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent limiter l'accès aux soins, affectant ainsi la santé globale des patients." } }, { "@type": "Question", "name": "Y a-t-il des symptômes financiers liés à la coassurance ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des frais médicaux imprévus peuvent entraîner des difficultés financières." } }, { "@type": "Question", "name": "Comment éviter des frais élevés de franchise ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Choisissez un plan avec une franchise adaptée à vos besoins médicaux prévisibles." } }, { "@type": "Question", "name": "Les bilans de santé sont-ils couverts sans franchise ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les bilans de santé préventifs sont couverts sans frais de franchise." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les franchises ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Fournissez des informations claires sur les coûts et les options d'assurance disponibles." } }, { "@type": "Question", "name": "Les programmes de prévention réduisent-ils les coûts ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire les coûts à long terme en évitant des soins coûteux." } }, { "@type": "Question", "name": "Comment les patients peuvent-ils planifier leurs soins ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Ils doivent évaluer leurs besoins et choisir des soins en fonction de leur plan d'assurance." } }, { "@type": "Question", "name": "Comment choisir un plan avec franchise ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Évaluez vos besoins médicaux et comparez les coûts des franchises et coassurances." } }, { "@type": "Question", "name": "Les traitements préventifs sont-ils couverts ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les traitements préventifs sont couverts sans franchise, selon le plan." } }, { "@type": "Question", "name": "Comment réduire les coûts de coassurance ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Choisissez des soins dans le réseau de votre assurance pour réduire les frais." } }, { "@type": "Question", "name": "Les médicaments sont-ils soumis à la franchise ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent être soumis à la franchise selon le plan d'assurance." } }, { "@type": "Question", "name": "Les soins d'urgence sont-ils affectés par la coassurance ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les soins d'urgence peuvent entraîner des frais de coassurance après la franchise." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des franchises élevées ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent retarder des soins nécessaires, entraînant des complications de santé." } }, { "@type": "Question", "name": "La coassurance peut-elle entraîner des complications financières ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des frais imprévus peuvent causer des dettes médicales importantes." } }, { "@type": "Question", "name": "Les patients évitent-ils des soins à cause des coûts ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les coûts élevés peuvent dissuader les patients de rechercher des soins médicaux." } }, { "@type": "Question", "name": "Comment les complications de santé affectent-elles les coûts ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent entraîner des frais médicaux supplémentaires et imprévus." } }, { "@type": "Question", "name": "Les complications dues à la coassurance sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux patients rencontrent des difficultés à payer leurs frais médicaux." } }, { "@type": "Question", "name": "Quels facteurs augmentent les coûts de franchise ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, les antécédents médicaux et le type de soins peuvent influencer les coûts." } }, { "@type": "Question", "name": "Comment le choix de l'assurance affecte-t-il les coûts ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Différents plans d'assurance ont des franchises et coassurances variées, influençant les coûts." } }, { "@type": "Question", "name": "Les maladies chroniques augmentent-elles les frais ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies chroniques peuvent faire face à des frais plus élevés." } }, { "@type": "Question", "name": "Les jeunes adultes ont-ils des franchises plus basses ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les jeunes adultes choisissent des plans avec des franchises plus basses." } }, { "@type": "Question", "name": "Les habitudes de santé influencent-elles les coûts ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de santé positives peuvent réduire les frais médicaux à long terme." } } ] } ] }

Sources (10000 au total)

Interleukin 1α and interleukin 18 in patients with vitiligo - Results of a case-control study.

Vitiligo is a depigmenting disorder resulting from loss of functional melanocytes in the skin. Variety of inflammatory mediators participate in the regulation of melanogenesis in melanocytes: interleu... Evaluation of IL-1α and IL-18 levels in peripheral blood in patients with vitiligo compared to healthy controls.... Fifty patients aged 18-81 with vitiligo participated in the study. The control group consisted of 38 healthy people. Venous blood samples were obtained from each participant. Serum IL-1α and IL-18 con... Among patients with vitiligo, the mean concentration of IL-1α was 0.13 (± 0.535) pg/mL, while in the control group it was 0.51 (± 1.51). There were no statistically significant differences in IL-1α co... There is no correlation between Il-1 and Il-18 concentration in the blood sera of patients with vitiligo....

The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases, including the cryopyrin- associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS... To establish evidence-based recommendations for diagnosis, treatment and monitoring of patients with IL-1 mediated autoinflammatory diseases to standardise their management.... A multinational, multidisciplinary task force consisting of physician experts, including rheumatologists, patients or caregivers and allied healthcare professionals, was established. Evidence synthesi... The task force devised five overarching principles, 14 statements related to diagnosis, 10 on therapy, and nine focused on long-term monitoring that were evidence and/or consensus-based for patients w... The 2021 EULAR/American College of Rheumatology points to consider represent state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitor...

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.

The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases, including the cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS)... To establish evidence-based recommendations for diagnosis, treatment and monitoring of patients with IL-1 mediated autoinflammatory diseases to standardise their management.... A multinational, multidisciplinary task force consisting of physician experts, including rheumatologists, patients or caregivers and allied healthcare professionals, was established. Evidence synthesi... The task force devised five overarching principles, 14 statements related to diagnosis, 10 on therapy, and nine focused on long-term monitoring that were evidence and/or consensus-based for patients w... The 2021 EULAR/American College of Rheumatology points to consider represent state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitor...

DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1.

DNA methyltransferase (DNMT) inhibitors are used for treatment of certain hematological malignancies and exert anti-cancer activity through diverse mechanisms, including reexpression of tumor suppress...

Methotrexate promotes the release of granulocyte-macrophage colony-stimulating factor from rheumatoid arthritis fibroblast-like synoviocytes via autocrine interleukin-1 signaling.

Activated fibroblast-like synoviocytes (FLS) are drivers of synovitis and structural joint damage in rheumatoid arthritis (RA). Despite the use of disease-modifying drugs, only about 50% of RA patient... Primary RA-FLS were activated by stimulation with interleukin-1β (IL-1β) or platelet-derived growth factor + IL-1β in the presence or absence of MTX or TOFA, with or without additional inhibitors. Co-... Six thousand three hundred fifty genes were differentially expressed, the majority being upregulated, in MTX-treated activated RA-FLS and 970 genes, the majority being downregulated, in TOFA-treated s... MTX treatment induces secretion of IL-1 from activated RA-FLS which by autocrine signaling augments their release of GM-CSF. This unexpected effect of MTX might contribute to the persistence of synovi...

miRNome and Proteome Profiling of Human Keratinocytes and Adipose Derived Stem Cells Proposed miRNA-Mediated Regulations of Epidermal Growth Factor and Interleukin 1-Alpha.

Wound healing is regulated by complex crosstalk between keratinocytes and other cell types, including stem cells. In this study, a 7-day direct co-culture model of human keratinocytes and adipose-deri...

Periodontal and peri-implant status and whole salivary interleukin 1-beta levels among individuals using selective serotonin reuptake inhibitors: an observational study.

Selective serotonin reuptake inhibitors (SSRI) are commonly used for managing psychological diseases such as depression. These disorders are also directly associated with periodontal and peri-implant ... Users of SSRI and controls were included. In all participants, periodontal (plaque index [PI], gingival index [GI], probing depth [PD], clinical attachment loss [AL] and marginal bone loss [MBL]) and ... Thirty-seven SSRI users and 35 controls were assessed. Individuals using SSRI had a history of depression of 4.2 ± 2.5 years. The mean age of SSRI-users and controls were 48.7 ± 5.7 and 45.3 ± 5.1 yea... Users of SSRI and controls demonstrate healthy periodontal and peri-implant tissue statuses with no marked differences in whole salivary IL-1β levels provided oral hygiene is stringently maintained....